[{"page":"46-47","quality_controlled":"1","article_type":"original","publisher":"Springer Nature","author":[{"full_name":"Glajzer, Jacek","last_name":"Glajzer","first_name":"Jacek"},{"first_name":"Dan Cacsire","last_name":"Castillo-Tong","full_name":"Castillo-Tong, Dan Cacsire"},{"full_name":"Richter, Rolf","last_name":"Richter","first_name":"Rolf"},{"full_name":"Vergote, Ignace","first_name":"Ignace","last_name":"Vergote"},{"full_name":"Kulbe, Hagen","last_name":"Kulbe","first_name":"Hagen"},{"full_name":"Vanderstichele, Adriaan","last_name":"Vanderstichele","first_name":"Adriaan"},{"first_name":"Ilary","last_name":"Ruscito","full_name":"Ruscito, Ilary"},{"full_name":"Trillsch, Fabian","first_name":"Fabian","last_name":"Trillsch"},{"full_name":"Mustea, Alexander","first_name":"Alexander","last_name":"Mustea"},{"full_name":"Kreuzinger, Caroline","last_name":"Kreuzinger","first_name":"Caroline","id":"382077BA-F248-11E8-B48F-1D18A9856A87"},{"full_name":"Gourley, Charlie","first_name":"Charlie","last_name":"Gourley"},{"full_name":"Gabra, Hani","last_name":"Gabra","first_name":"Hani"},{"first_name":"Eliane T.","last_name":"Taube","full_name":"Taube, Eliane T."},{"last_name":"Dorigo","first_name":"Oliver","full_name":"Dorigo, Oliver"},{"first_name":"David","last_name":"Horst","full_name":"Horst, David"},{"full_name":"Keunecke, Carlotta","last_name":"Keunecke","first_name":"Carlotta"},{"full_name":"Baum, Joanna","last_name":"Baum","first_name":"Joanna"},{"full_name":"Angelotti, Timothy","first_name":"Timothy","last_name":"Angelotti"},{"first_name":"Jalid","last_name":"Sehouli","full_name":"Sehouli, Jalid"},{"full_name":"Braicu, Elena Ioana","last_name":"Braicu","first_name":"Elena Ioana"}],"_id":"12115","scopus_import":"1","title":"ASO Visual Abstract: Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome, and patient survival in primary and recurrent high-grade serous ovarian cancer (HGSOC). A multicenter, retrospective study of the ovarian cancer therapy—innovative models prolong survival (OCTIPS) consortium","intvolume":"        30","publication_status":"published","article_processing_charge":"No","department":[{"_id":"JoDa"}],"date_created":"2023-01-12T11:56:22Z","volume":30,"acknowledgement":"This work was supported by European Commission’s Seventh Framework Programme under Grant Agreement No. 279113 (OCTIPS; www.octips.eu).","isi":1,"external_id":{"isi":["000879151800001"]},"date_updated":"2023-09-05T15:18:36Z","citation":{"ista":"Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI. 2023. ASO Visual Abstract: Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome, and patient survival in primary and recurrent high-grade serous ovarian cancer (HGSOC). A multicenter, retrospective study of the ovarian cancer therapy—innovative models prolong survival (OCTIPS) consortium. Annals of Surgical Oncology. 30, 46–47.","mla":"Glajzer, Jacek, et al. “ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) Consortium.” <i>Annals of Surgical Oncology</i>, vol. 30, Springer Nature, 2023, pp. 46–47, doi:<a href=\"https://doi.org/10.1245/s10434-022-12681-z\">10.1245/s10434-022-12681-z</a>.","short":"J. Glajzer, D.C. Castillo-Tong, R. Richter, I. Vergote, H. Kulbe, A. Vanderstichele, I. Ruscito, F. Trillsch, A. Mustea, C. Kreuzinger, C. Gourley, H. Gabra, E.T. Taube, O. Dorigo, D. Horst, C. Keunecke, J. Baum, T. Angelotti, J. Sehouli, E.I. Braicu, Annals of Surgical Oncology 30 (2023) 46–47.","ieee":"J. Glajzer <i>et al.</i>, “ASO Visual Abstract: Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome, and patient survival in primary and recurrent high-grade serous ovarian cancer (HGSOC). A multicenter, retrospective study of the ovarian cancer therapy—innovative models prolong survival (OCTIPS) consortium,” <i>Annals of Surgical Oncology</i>, vol. 30. Springer Nature, pp. 46–47, 2023.","chicago":"Glajzer, Jacek, Dan Cacsire Castillo-Tong, Rolf Richter, Ignace Vergote, Hagen Kulbe, Adriaan Vanderstichele, Ilary Ruscito, et al. “ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) Consortium.” <i>Annals of Surgical Oncology</i>. Springer Nature, 2023. <a href=\"https://doi.org/10.1245/s10434-022-12681-z\">https://doi.org/10.1245/s10434-022-12681-z</a>.","ama":"Glajzer J, Castillo-Tong DC, Richter R, et al. ASO Visual Abstract: Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome, and patient survival in primary and recurrent high-grade serous ovarian cancer (HGSOC). A multicenter, retrospective study of the ovarian cancer therapy—innovative models prolong survival (OCTIPS) consortium. <i>Annals of Surgical Oncology</i>. 2023;30:46-47. doi:<a href=\"https://doi.org/10.1245/s10434-022-12681-z\">10.1245/s10434-022-12681-z</a>","apa":"Glajzer, J., Castillo-Tong, D. C., Richter, R., Vergote, I., Kulbe, H., Vanderstichele, A., … Braicu, E. I. (2023). ASO Visual Abstract: Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome, and patient survival in primary and recurrent high-grade serous ovarian cancer (HGSOC). A multicenter, retrospective study of the ovarian cancer therapy—innovative models prolong survival (OCTIPS) consortium. <i>Annals of Surgical Oncology</i>. Springer Nature. <a href=\"https://doi.org/10.1245/s10434-022-12681-z\">https://doi.org/10.1245/s10434-022-12681-z</a>"},"year":"2023","doi":"10.1245/s10434-022-12681-z","day":"01","language":[{"iso":"eng"}],"keyword":["Oncology","Surgery"],"publication":"Annals of Surgical Oncology","month":"01","oa_version":"Published Version","user_id":"c635000d-4b10-11ee-a964-aac5a93f6ac1","status":"public","related_material":{"record":[{"status":"public","id":"12205","relation":"other"}]},"main_file_link":[{"url":"https://doi.org/10.1245/s10434-022-12681-z","open_access":"1"}],"date_published":"2023-01-01T00:00:00Z","type":"journal_article","oa":1,"publication_identifier":{"issn":["1068-9265"],"eissn":["1534-4681"]}},{"keyword":["Oncology","Surgery"],"language":[{"iso":"eng"}],"has_accepted_license":"1","publication":"Annals of Surgical Oncology","oa_version":"Published Version","month":"01","file":[{"date_created":"2023-02-02T13:01:20Z","checksum":"36a1200e1011f4b2155a8041d0308f34","file_size":365865,"date_updated":"2023-02-02T13:01:20Z","content_type":"application/pdf","file_name":"2023_AnnalsSurgicalOncology_Glajzer.pdf","relation":"main_file","success":1,"access_level":"open_access","file_id":"12490","creator":"dernst"}],"status":"public","related_material":{"record":[{"relation":"other","id":"12115","status":"public"}]},"user_id":"c635000d-4b10-11ee-a964-aac5a93f6ac1","tmp":{"legal_code_url":"https://creativecommons.org/licenses/by/4.0/legalcode","short":"CC BY (4.0)","image":"/images/cc_by.png","name":"Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)"},"type":"journal_article","date_published":"2023-01-01T00:00:00Z","publication_identifier":{"issn":["1068-9265"],"eissn":["1534-4681"]},"oa":1,"quality_controlled":"1","page":"35-45","file_date_updated":"2023-02-02T13:01:20Z","publisher":"Springer Nature","article_type":"original","scopus_import":"1","_id":"12205","author":[{"last_name":"Glajzer","first_name":"Jacek","full_name":"Glajzer, Jacek"},{"full_name":"Castillo-Tong, Dan Cacsire","last_name":"Castillo-Tong","first_name":"Dan Cacsire"},{"first_name":"Rolf","last_name":"Richter","full_name":"Richter, Rolf"},{"first_name":"Ignace","last_name":"Vergote","full_name":"Vergote, Ignace"},{"last_name":"Kulbe","first_name":"Hagen","full_name":"Kulbe, Hagen"},{"first_name":"Adriaan","last_name":"Vanderstichele","full_name":"Vanderstichele, Adriaan"},{"full_name":"Ruscito, Ilary","last_name":"Ruscito","first_name":"Ilary"},{"full_name":"Trillsch, Fabian","last_name":"Trillsch","first_name":"Fabian"},{"full_name":"Mustea, Alexander","last_name":"Mustea","first_name":"Alexander"},{"full_name":"Kreuzinger, Caroline","first_name":"Caroline","last_name":"Kreuzinger","id":"382077BA-F248-11E8-B48F-1D18A9856A87"},{"full_name":"Gourley, Charlie","first_name":"Charlie","last_name":"Gourley"},{"full_name":"Gabra, Hani","last_name":"Gabra","first_name":"Hani"},{"full_name":"Taube, Eliane T.","last_name":"Taube","first_name":"Eliane T."},{"full_name":"Dorigo, Oliver","first_name":"Oliver","last_name":"Dorigo"},{"first_name":"David","last_name":"Horst","full_name":"Horst, David"},{"full_name":"Keunecke, Carlotta","last_name":"Keunecke","first_name":"Carlotta"},{"last_name":"Baum","first_name":"Joanna","full_name":"Baum, Joanna"},{"full_name":"Angelotti, Timothy","last_name":"Angelotti","first_name":"Timothy"},{"first_name":"Jalid","last_name":"Sehouli","full_name":"Sehouli, Jalid"},{"first_name":"Elena Ioana","last_name":"Braicu","full_name":"Braicu, Elena Ioana"}],"date_created":"2023-01-16T09:44:36Z","department":[{"_id":"JoDa"}],"article_processing_charge":"No","publication_status":"published","intvolume":"        30","title":"Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: A multicenter retrospective study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) consortium","volume":30,"acknowledgement":"E.I.B. is a Feodor Lynen fellow of the Humboldt Foundation and a participant of the Charité Clinical Scientist Program funded by the Charité Universitätsmedizin Berlin and the Berlin Institute of Health. This work was supported by European Commission’s Seventh Framework Programme under grant agreement no. 279113 (OCTIPS; www.octips.eu).\r\nOpen Access funding enabled and organized by Projekt DEAL.","ddc":["610"],"year":"2023","citation":{"ista":"Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI. 2023. Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: A multicenter retrospective study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) consortium. Annals of Surgical Oncology. 30, 35–45.","short":"J. Glajzer, D.C. Castillo-Tong, R. Richter, I. Vergote, H. Kulbe, A. Vanderstichele, I. Ruscito, F. Trillsch, A. Mustea, C. Kreuzinger, C. Gourley, H. Gabra, E.T. Taube, O. Dorigo, D. Horst, C. Keunecke, J. Baum, T. Angelotti, J. Sehouli, E.I. Braicu, Annals of Surgical Oncology 30 (2023) 35–45.","mla":"Glajzer, Jacek, et al. “Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.” <i>Annals of Surgical Oncology</i>, vol. 30, Springer Nature, 2023, pp. 35–45, doi:<a href=\"https://doi.org/10.1245/s10434-022-12459-3\">10.1245/s10434-022-12459-3</a>.","chicago":"Glajzer, Jacek, Dan Cacsire Castillo-Tong, Rolf Richter, Ignace Vergote, Hagen Kulbe, Adriaan Vanderstichele, Ilary Ruscito, et al. “Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.” <i>Annals of Surgical Oncology</i>. Springer Nature, 2023. <a href=\"https://doi.org/10.1245/s10434-022-12459-3\">https://doi.org/10.1245/s10434-022-12459-3</a>.","ieee":"J. Glajzer <i>et al.</i>, “Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: A multicenter retrospective study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) consortium,” <i>Annals of Surgical Oncology</i>, vol. 30. Springer Nature, pp. 35–45, 2023.","apa":"Glajzer, J., Castillo-Tong, D. C., Richter, R., Vergote, I., Kulbe, H., Vanderstichele, A., … Braicu, E. I. (2023). Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: A multicenter retrospective study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) consortium. <i>Annals of Surgical Oncology</i>. Springer Nature. <a href=\"https://doi.org/10.1245/s10434-022-12459-3\">https://doi.org/10.1245/s10434-022-12459-3</a>","ama":"Glajzer J, Castillo-Tong DC, Richter R, et al. Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: A multicenter retrospective study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) consortium. <i>Annals of Surgical Oncology</i>. 2023;30:35-45. doi:<a href=\"https://doi.org/10.1245/s10434-022-12459-3\">10.1245/s10434-022-12459-3</a>"},"date_updated":"2023-09-05T15:18:37Z","external_id":{"isi":["000852125500006"]},"isi":1,"day":"01","doi":"10.1245/s10434-022-12459-3","abstract":[{"lang":"eng","text":"Background: This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dissemination pattern, surgical outcome and survival in a multicenter cohort of paired primary ovarian cancer (pOC) and recurrent ovarian cancer (rOC).\r\n\r\nPatients and Methods: Medical records and follow-up data from 190 patients were gathered retrospectively. All patients had surgery at pOC and at least one further rOC surgery at four European high-volume centers. Patients were divided into one cohort with confirmed mutation for BRCA1 and/or BRCA2 (BRCAmut) and a second cohort with BRCA wild type or unknown (BRCAwt). Patterns of tumor presentation, surgical outcome and survival data were analyzed between the two groups.\r\n\r\nResults: Patients with BRCAmut disease were on average 4 years younger and had significantly more tumor involvement upon diagnosis. Patients with BRCAmut disease showed higher debulking rates at all stages. Multivariate analysis showed that only patient age had significant predictive value for complete tumor resection in pOC. At rOC, however, only BRCAmut status significantly correlated with optimal debulking. Patients with BRCAmut disease showed significantly prolonged overall survival (OS) by 24.3 months. Progression-free survival (PFS) was prolonged in the BRCAmut group at all stages as well, reaching statistical significance during recurrence.\r\n\r\nConclusions: Patients with BRCAmut disease showed a more aggressive course of disease with earlier onset and more extensive tumor dissemination at pOC. However, surgical outcome and OS were significantly better in patients with BRCAmut disease compared with patients with BRCAwt disease. We therefore propose to consider BRCAmut status in regard to patient selection for cytoreductive surgery, especially in rOC."}]},{"oa_version":"Published Version","article_number":"983507","month":"08","has_accepted_license":"1","publication":"Frontiers in Oncology","keyword":["Cancer Research","Oncology"],"language":[{"iso":"eng"}],"publication_identifier":{"issn":["2234-943X"]},"oa":1,"tmp":{"legal_code_url":"https://creativecommons.org/licenses/by/4.0/legalcode","short":"CC BY (4.0)","image":"/images/cc_by.png","name":"Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)"},"type":"journal_article","date_published":"2022-08-25T00:00:00Z","file":[{"relation":"main_file","success":1,"access_level":"open_access","file_id":"12450","creator":"dernst","date_created":"2023-01-30T10:25:21Z","file_size":13588502,"checksum":"efc7edf9f626af31853790c5b598a68c","date_updated":"2023-01-30T10:25:21Z","file_name":"2022_FrontiersOntology_Basilico.pdf","content_type":"application/pdf"}],"user_id":"4359f0d1-fa6c-11eb-b949-802e58b17ae8","status":"public","date_created":"2023-01-16T10:00:28Z","department":[{"_id":"GaNo"}],"article_processing_charge":"No","publication_status":"published","intvolume":"        12","title":"Substrate stiffness effect on molecular crosstalk of epithelial-mesenchymal transition mediators of human glioblastoma cells","scopus_import":"1","pmid":1,"_id":"12268","author":[{"id":"36035796-5ACA-11E9-A75E-7AF2E5697425","orcid":"0000-0003-1843-3173","full_name":"Basilico, Bernadette","first_name":"Bernadette","last_name":"Basilico"},{"full_name":"Palamà, Ilaria Elena","first_name":"Ilaria Elena","last_name":"Palamà"},{"full_name":"D’Amone, Stefania","first_name":"Stefania","last_name":"D’Amone"},{"first_name":"Clotilde","last_name":"Lauro","full_name":"Lauro, Clotilde"},{"last_name":"Rosito","first_name":"Maria","full_name":"Rosito, Maria"},{"full_name":"Grieco, Maddalena","first_name":"Maddalena","last_name":"Grieco"},{"last_name":"Ratano","first_name":"Patrizia","full_name":"Ratano, Patrizia"},{"last_name":"Cordella","first_name":"Federica","full_name":"Cordella, Federica"},{"last_name":"Sanchini","first_name":"Caterina","full_name":"Sanchini, Caterina"},{"last_name":"Di Angelantonio","first_name":"Silvia","full_name":"Di Angelantonio, Silvia"},{"full_name":"Ragozzino, Davide","last_name":"Ragozzino","first_name":"Davide"},{"last_name":"Cascione","first_name":"Mariafrancesca","full_name":"Cascione, Mariafrancesca"},{"full_name":"Gigli, Giuseppe","first_name":"Giuseppe","last_name":"Gigli"},{"first_name":"Barbara","last_name":"Cortese","full_name":"Cortese, Barbara"}],"publisher":"Frontiers Media","article_type":"original","quality_controlled":"1","file_date_updated":"2023-01-30T10:25:21Z","day":"25","doi":"10.3389/fonc.2022.983507","abstract":[{"lang":"eng","text":"The complexity of the microenvironment effects on cell response, show accumulating evidence that glioblastoma (GBM) migration and invasiveness are influenced by the mechanical rigidity of their surroundings. The epithelial–mesenchymal transition (EMT) is a well-recognized driving force of the invasive behavior of cancer. However, the primary mechanisms of EMT initiation and progression remain unclear. We have previously showed that certain substrate stiffness can selectively stimulate human GBM U251-MG and GL15 glioblastoma cell lines motility. The present study unifies several known EMT mediators to uncover the reason of the regulation and response to these stiffnesses. Our results revealed that changing the rigidity of the mechanical environment tuned the response of both cell lines through change in morphological features, epithelial-mesenchymal markers (E-, N-Cadherin), EGFR and ROS expressions in an interrelated manner. Specifically, a stiffer microenvironment induced a mesenchymal cell shape, a more fragmented morphology, higher intracellular cytosolic ROS expression and lower mitochondrial ROS. Finally, we observed that cells more motile showed a more depolarized mitochondrial membrane potential. Unravelling the process that regulates GBM cells’ infiltrative behavior could provide new opportunities for identification of new targets and less invasive approaches for treatment."}],"year":"2022","citation":{"ieee":"B. Basilico <i>et al.</i>, “Substrate stiffness effect on molecular crosstalk of epithelial-mesenchymal transition mediators of human glioblastoma cells,” <i>Frontiers in Oncology</i>, vol. 12. Frontiers Media, 2022.","chicago":"Basilico, Bernadette, Ilaria Elena Palamà, Stefania D’Amone, Clotilde Lauro, Maria Rosito, Maddalena Grieco, Patrizia Ratano, et al. “Substrate Stiffness Effect on Molecular Crosstalk of Epithelial-Mesenchymal Transition Mediators of Human Glioblastoma Cells.” <i>Frontiers in Oncology</i>. Frontiers Media, 2022. <a href=\"https://doi.org/10.3389/fonc.2022.983507\">https://doi.org/10.3389/fonc.2022.983507</a>.","ama":"Basilico B, Palamà IE, D’Amone S, et al. Substrate stiffness effect on molecular crosstalk of epithelial-mesenchymal transition mediators of human glioblastoma cells. <i>Frontiers in Oncology</i>. 2022;12. doi:<a href=\"https://doi.org/10.3389/fonc.2022.983507\">10.3389/fonc.2022.983507</a>","apa":"Basilico, B., Palamà, I. E., D’Amone, S., Lauro, C., Rosito, M., Grieco, M., … Cortese, B. (2022). Substrate stiffness effect on molecular crosstalk of epithelial-mesenchymal transition mediators of human glioblastoma cells. <i>Frontiers in Oncology</i>. Frontiers Media. <a href=\"https://doi.org/10.3389/fonc.2022.983507\">https://doi.org/10.3389/fonc.2022.983507</a>","ista":"Basilico B, Palamà IE, D’Amone S, Lauro C, Rosito M, Grieco M, Ratano P, Cordella F, Sanchini C, Di Angelantonio S, Ragozzino D, Cascione M, Gigli G, Cortese B. 2022. Substrate stiffness effect on molecular crosstalk of epithelial-mesenchymal transition mediators of human glioblastoma cells. Frontiers in Oncology. 12, 983507.","mla":"Basilico, Bernadette, et al. “Substrate Stiffness Effect on Molecular Crosstalk of Epithelial-Mesenchymal Transition Mediators of Human Glioblastoma Cells.” <i>Frontiers in Oncology</i>, vol. 12, 983507, Frontiers Media, 2022, doi:<a href=\"https://doi.org/10.3389/fonc.2022.983507\">10.3389/fonc.2022.983507</a>.","short":"B. Basilico, I.E. Palamà, S. D’Amone, C. Lauro, M. Rosito, M. Grieco, P. Ratano, F. Cordella, C. Sanchini, S. Di Angelantonio, D. Ragozzino, M. Cascione, G. Gigli, B. Cortese, Frontiers in Oncology 12 (2022)."},"date_updated":"2023-08-04T09:54:16Z","external_id":{"pmid":["36091138"],"isi":["000856524900001"]},"isi":1,"acknowledgement":"The research leading to these results has received funding from AIRC under IG 2021 - ID. 26328 project – P.I. Cortese Barbara and AIRC under MFAG 2015 - ID. 16803 project – “P.I. Cortese Barbara”. The authors are also grateful to the ”Tecnopolo per la medicina di precisione” (TecnoMed Puglia) - Regione Puglia: DGR n.2117 del 21/11/2018, CUP: B84I18000540002 and “Tecnopolo di Nanotecnologia e Fotonica per la medicina di precisione” (TECNOMED) - FISR/MIUR-CNR: delibera CIPE n.3449 del 7-08-2017, CUP: B83B17000010001.\r\nWe thank Dr. Francesca Pagani for useful technical support. We thank also Irene Iacuitto, Giovanna Loffredo and Manuela Marchetti for practical administrative support.","volume":12,"ddc":["570"]}]